Key Highlights
- IBO shares climbed more than 115% during pre-market hours following an SEC Form 8-K filing announcing merger modifications
- The completion deadline for the Dr Ashleys Limited merger moved from March 31 to July 1, 2026
- Impact BioMedical will obtain 169.56 million PubCo Ordinary Shares, representing 94.20% ownership in the merged entity
- DSS, Inc. — controlling 88.87% of IBO on a fully diluted basis — will obtain 53,000 shares related to indemnification requirements
- IBO’s previous closing price stood at $0.41, within a yearly trading range spanning $0.36 to $6.17
Impact BioMedical submitted a Form 8-K filing on March 5, 2026, outlining multiple amendments to its merger arrangement with Dr Ashleys Bio Labs Limited, a pharmaceutical enterprise based in the Cayman Islands.
Shares climbed beyond 115% during pre-market trading hours, reaching $0.85 after ending the previous session at $0.41.
The original merger agreement received signatures on June 21, 2025. The updated amendments extend the deal’s “End Date” by three months — moving from March 31, 2026, to July 1, 2026.
This extension provides additional time for both companies to satisfy all necessary closing conditions.
A significant modification in the updated agreement mandates that IBO secure board authorization before executing any new loan arrangements prior to completing the merger.
According to the modified equity allocation, Impact BioMedical will obtain 169,560,000 PubCo Ordinary Shares upon deal completion. This figure equals 94.20% of the consolidated company, with performance-based shares, CEO compensation shares, and DSS-related issuances excluded from the calculation.
Equity Distribution and DSS Involvement
DSS, Inc. serves as IBO’s parent entity. The company controls roughly 88.87% of IBO on a fully diluted basis, working alongside DSS BioHealth Security, Inc.
According to the modified Transition Arrangement Agreement, DSS will obtain 53,000 ordinary shares of Dr Ashleys Limited when the deal closes to address hold harmless obligations.
An additional 75,000 shares will transfer to DSS upon complete satisfaction of its funding commitments outlined in the revised agreement.
The Voting and Support Agreement received corresponding updates. Supporting stockholders now control a verified 92,980,843 IBO shares, equal to 88.87% on a fully diluted basis after converting preferred shares and promissory notes.
IBO’s Trading Performance Background
Before Wednesday’s after-hours movement and Thursday’s pre-market rally, IBO had declined 71.30% during the preceding 12-month period.
The shares have traded within a 52-week range spanning $0.36 to $6.17, hovering near the lower boundary before the merger announcement emerged.
IBO’s market capitalization measured approximately $43.24 million.
The Relative Strength Index (RSI) registers at 39.62, indicating the stock’s fragile technical standing entering this trading week.
Wednesday’s after-hours session witnessed IBO advance 86.28% to $0.77 before the pre-market rally carried shares above $0.85.
